218 related articles for article (PubMed ID: 37506139)
1. Immunomodulatory role of spleen tyrosine kinase in chronic inflammatory and autoimmune diseases.
Zhou Y; Zhang Y; Yu W; Qin Y; He H; Dai F; Wang Y; Zhu F; Zhou G
Immun Inflamm Dis; 2023 Jul; 11(7):e934. PubMed ID: 37506139
[TBL] [Abstract][Full Text] [Related]
2. [Involvement of Syk in pathology of systemic autoimmune disease].
Iwata S; Yamaoka K; Niiro H; Nakano K; Wang SP; Saito K; Akashi K; Tanaka Y
Nihon Rinsho Meneki Gakkai Kaishi; 2012; 35(1):56-61. PubMed ID: 22374444
[TBL] [Abstract][Full Text] [Related]
3. Recent advance of spleen tyrosine kinase in diseases and drugs.
Shao Y; Zhang S; Zhang Y; Liu Z
Int Immunopharmacol; 2021 Jan; 90():107168. PubMed ID: 33264719
[TBL] [Abstract][Full Text] [Related]
4. Inhibitors of switch kinase 'spleen tyrosine kinase' in inflammation and immune-mediated disorders: a review.
Kaur M; Singh M; Silakari O
Eur J Med Chem; 2013 Sep; 67():434-46. PubMed ID: 23917087
[TBL] [Abstract][Full Text] [Related]
5. Recent advances in understanding spleen tyrosine kinase (SYK) in human biology and disease, with a focus on fostamatinib.
Cooper N; Ghanima W; Hill QA; Nicolson PL; Markovtsov V; Kessler C
Platelets; 2023 Dec; 34(1):2131751. PubMed ID: 36331249
[TBL] [Abstract][Full Text] [Related]
6. The selective inhibition of the Syk tyrosine kinase ameliorates experimental autoimmune arthritis.
Káposztás E; Balogh L; Mócsai A; Kemecsei É; Jakus Z; Németh T
Front Immunol; 2023; 14():1279155. PubMed ID: 38111569
[TBL] [Abstract][Full Text] [Related]
7. TAS05567, a Novel Potent and Selective Spleen Tyrosine Kinase Inhibitor, Abrogates Immunoglobulin-Mediated Autoimmune and Allergic Reactions in Rodent Models.
Hayashi H; Kaneko R; Demizu S; Akasaka D; Tayama M; Harada T; Irie H; Ogino Y; Fujino N; Sasaki E
J Pharmacol Exp Ther; 2018 Jul; 366(1):84-95. PubMed ID: 29728446
[TBL] [Abstract][Full Text] [Related]
8. Spleen tyrosine kinase inhibition blocks airway constriction and protects from Th2-induced airway inflammation and remodeling.
Tabeling C; Herbert J; Hocke AC; Lamb DJ; Wollin SL; Erb KJ; Boiarina E; Movassagh H; Scheffel J; Doehn JM; Hippenstiel S; Maurer M; Gounni AS; Kuebler WM; Suttorp N; Witzenrath M
Allergy; 2017 Jul; 72(7):1061-1072. PubMed ID: 27906453
[TBL] [Abstract][Full Text] [Related]
9. Targeting Syk in Autoimmune Rheumatic Diseases.
Deng GM; Kyttaris VC; Tsokos GC
Front Immunol; 2016; 7():78. PubMed ID: 27014261
[TBL] [Abstract][Full Text] [Related]
10. Role of spleen tyrosine kinase in liver diseases.
Kurniawan DW; Storm G; Prakash J; Bansal R
World J Gastroenterol; 2020 Mar; 26(10):1005-1019. PubMed ID: 32205992
[TBL] [Abstract][Full Text] [Related]
11. Spleen tyrosine kinase (SYK) is a potential target for the treatment of cutaneous lupus erythematosus patients.
Braegelmann C; Hölzel M; Ludbrook V; Dickson M; Turan N; Ferring-Schmitt S; Sternberg S; Bieber T; Kuhn A; Wenzel J
Exp Dermatol; 2016 May; 25(5):375-9. PubMed ID: 26910509
[TBL] [Abstract][Full Text] [Related]
12. Sympathetic Nerve Hyperactivity in the Spleen: Causal for Nonpathogenic-Driven Chronic Immune-Mediated Inflammatory Diseases (IMIDs)?
Bellinger DL; Lorton D
Int J Mol Sci; 2018 Apr; 19(4):. PubMed ID: 29652832
[TBL] [Abstract][Full Text] [Related]
13. Spleen tyrosine kinase inhibition in the treatment of autoimmune, allergic and autoinflammatory diseases.
Pamuk ON; Tsokos GC
Arthritis Res Ther; 2010; 12(6):222. PubMed ID: 21211067
[TBL] [Abstract][Full Text] [Related]
14. Selective inhibition of spleen tyrosine kinase (SYK) with a novel orally bioavailable small molecule inhibitor, RO9021, impinges on various innate and adaptive immune responses: implications for SYK inhibitors in autoimmune disease therapy.
Liao C; Hsu J; Kim Y; Hu DQ; Xu D; Zhang J; Pashine A; Menke J; Whittard T; Romero N; Truitt T; Slade M; Lukacs C; Hermann J; Zhou M; Lucas M; Narula S; DeMartino J; Tan SL
Arthritis Res Ther; 2013 Oct; 15(5):R146. PubMed ID: 24286216
[TBL] [Abstract][Full Text] [Related]
15. Preclinical Pharmacology Characterization of Sovleplenib (HMPL-523), an Orally Available Syk Inhibitor.
Cai Y; He J; Wu Z; He W; Dai X; Xu Y; Cheng M; Yang N; Ren Y; Wang G; Wang J; Sai Y; Jia H; Dai G; Li X; Su W
J Pharmacol Exp Ther; 2024 Jan; 388(1):156-170. PubMed ID: 37918855
[TBL] [Abstract][Full Text] [Related]
16. A novel selective spleen tyrosine kinase inhibitor SKI-O-703 (cevidoplenib) ameliorates lupus nephritis and serum-induced arthritis in murine models.
Cho S; Jang E; Yoon T; Hwang H; Youn J
Clin Exp Immunol; 2023 Mar; 211(1):31-45. PubMed ID: 36346114
[TBL] [Abstract][Full Text] [Related]
17. Investigational spleen tyrosine kinase (SYK) inhibitors for the treatment of autoimmune diseases.
Tang S; Yu Q; Ding C
Expert Opin Investig Drugs; 2022 Mar; 31(3):291-303. PubMed ID: 35130124
[TBL] [Abstract][Full Text] [Related]
18. Spleen Tyrosine Kinase: A Crucial Player and Potential Therapeutic Target in Renal Disease.
Ma TK; McAdoo SP; Tam FW
Nephron; 2016; 133(4):261-9. PubMed ID: 27476075
[TBL] [Abstract][Full Text] [Related]
19. The role of Syk/IĸB-α/NF-ĸB pathway activation in the reversal effect of BAY 61-3606, a selective Syk inhibitor, on hypotension and inflammation in a rat model of zymosan-induced non-septic shock.
Unsal D; Kacan M; Temiz-Resitoglu M; Guden DS; Korkmaz B; Sari AN; Buharalioglu CK; Yildirim-Yaroglu H; Tamer-Gumus L; Tunctan B; Malik KU; Sahan-Firat S
Clin Exp Pharmacol Physiol; 2018 Feb; 45(2):155-165. PubMed ID: 28949404
[TBL] [Abstract][Full Text] [Related]
20. Spleen Tyrosine Kinase as a Target Therapy for Pseudomonas aeruginosa Infection.
Alhazmi A
J Innate Immun; 2018; 10(4):255-263. PubMed ID: 29925062
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
